SCHEMBL4183644

SCHEMBL4183644

O=C(Cc1ccc(C(F)(F)F)cc1)c1c(O)c2cccnc2n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.43
POLB P06746 2/20 0.43
TRPV1 Q8NER1 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4D Q08499 1/20 0.41
PPARG P37231 1/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
THRB P10828 1/20 0.41
HPGD P15428 1/20 0.41
EP300 Q09472 1/20 0.39
CREBBP Q92793 1/20 0.39
KAT2A Q92830 1/20 0.39
KAT2B Q92831 1/20 0.39
LMNA P02545 1/20 0.39
CXCR3 P49682 1/20 0.38
ELANE P08246 2/20 0.38
PIK3CA P42336 1/20 0.38
NPY5R Q15761 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4195071 0.94 CNR2 (0.44) TP53POLBTRPV1PDE4BPDE4D
SCHEMBL4187658 0.94 POLB (0.47) TP53POLBTRPV1PDE4BPDE4D
SCHEMBL4183574 0.93 TP53 (0.44) TP53POLBTRPV1PDE4BPDE4D
SCHEMBL4189465 0.91 BCL2L1 (0.42) TP53POLBTRPV1PDE4BPDE4D
SCHEMBL4187079 0.90 PDE4B (0.41) TP53POLBPTGDR2PDE4BPDE4D
SCHEMBL4185752 0.89 TP53 (0.47) TP53POLBTRPV1PDE4BPDE4D
SCHEMBL4190734 0.87 PPARG (0.41) TP53POLBTRPV1PDE4BPDE4D
SCHEMBL4187214 0.86 POLB (0.45) TP53POLBTRPV1PTGDR2PDE4B
SCHEMBL13685422 0.86 TP53 (0.40) TP53POLBTRPV1PDE4BPDE4D
SCHEMBL4187633 0.86 PPARG (0.41) TP53POLBTRPV1PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A TP53 4856/4885POLB 1630/4885TRPV1 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.